Squarepoint’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-27,629
| Closed | -$645K | – | 4367 |
|
|
2025
Q4 | $645K | Sell |
27,629
-80,970
| -75% | -$1.8M | ﹤0.01% | 2996 |
|
|
2025
Q3 | $2.14M | Buy |
108,599
+57,927
| +114% | +$1.19M | ﹤0.01% | 2039 |
|
|
2025
Q2 | $1.1M | Sell |
50,672
-23,922
| -32% | -$565K | ﹤0.01% | 2588 |
|
|
2025
Q1 | $1.81M | Sell |
74,594
-37,111
| -33% | -$836K | ﹤0.01% | 2180 |
|
|
2024
Q4 | $2.33M | Buy |
111,705
+30,842
| +38% | +$663K | ﹤0.01% | 2289 |
|
|
2024
Q3 | $1.61M | Buy |
80,863
+62,591
| +343% | +$1.16M | ﹤0.01% | 2231 |
|
|
2024
Q2 | $283K | Sell |
18,272
-170,088
| -90% | -$2.65M | ﹤0.01% | 3459 |
|
|
2024
Q1 | $3M | Buy |
+188,360
| New | +$2.84M | 0.01% | 1822 |
|
|
2023
Q4 | – | Sell |
-41,798
| Closed | -$489K | – | 4066 |
|
|
2023
Q3 | $489K | Buy |
+41,798
| New | +$559K | ﹤0.01% | 2822 |
|
|
2023
Q2 | – | Sell |
-66,586
| Closed | -$1.1M | – | 3625 |
|
|
2023
Q1 | $1.1M | Buy |
+66,586
| New | +$1.1M | ﹤0.01% | 1820 |
|
|
2022
Q1 | – | Sell |
-89,336
| Closed | -$605K | – | 2925 |
|
|
2021
Q4 | $605K | Buy |
+89,336
| New | +$587K | ﹤0.01% | 2021 |
|
|
2021
Q2 | – | Sell |
-75,781
| Closed | -$349K | – | 3295 |
|
|
2021
Q1 | $349K | Sell |
75,781
-26,575
| -26% | -$106K | ﹤0.01% | 2291 |
|
|
2020
Q4 | $342K | Buy |
102,356
+38,099
| +59% | +$128K | ﹤0.01% | 2111 |
|
|
2020
Q3 | $191K | Buy |
+64,257
| New | +$251K | ﹤0.01% | 2113 |
|
|
2020
Q2 | – | Sell |
-247,194
| Closed | -$952K | – | 2265 |
|
|
2020
Q1 | $952K | Sell |
247,194
-756,848
| -75% | -$3.11M | 0.02% | 736 |
|
|
2019
Q4 | $3.77M | Buy |
1,004,042
+989,519
| +6,813% | +$4.63M | 0.02% | 603 |
|
|
2019
Q3 | $77K | Sell |
14,523
-25,977
| -64% | -$138K | ﹤0.01% | 2214 |
|
|
2019
Q2 | $156K | Buy |
+40,500
| New | +$175K | ﹤0.01% | 2157 |
|
|
2019
Q1 | – | Sell |
-45,147
| Closed | -$87K | – | 2180 |
|
|
2018
Q4 | $87K | Buy |
+45,147
| New | +$129K | ﹤0.01% | 1808 |
|
|
2018
Q3 | – | Sell |
-201,450
| Closed | -$629K | – | 2012 |
|
|
2018
Q2 | $629K | Buy |
201,450
+72,950
| +57% | +$221K | 0.01% | 1083 |
|
|
2018
Q1 | $307K | Sell |
128,500
-58,143
| -31% | -$193K | ﹤0.01% | 1307 |
|
|
2017
Q4 | $730K | Buy |
186,643
+109,743
| +143% | +$363K | 0.01% | 977 |
|
|
2017
Q3 | $194K | Buy |
76,900
+16,400
| +27% | +$45K | ﹤0.01% | 1397 |
|
|
2017
Q2 | $167K | Buy |
+60,500
| New | +$126K | ﹤0.01% | 1343 |
|
|
2017
Q1 | – | Sell |
-18,000
| Closed | -$19K | – | 1569 |
|
|
2016
Q4 | $19K | Buy |
+18,000
| New | +$20.6K | ﹤0.01% | 1727 |
|
|
2016
Q3 | – | Sell |
-41,400
| Closed | -$29K | – | 1045 |
|
|
2016
Q2 | $29K | Buy |
+41,400
| New | +$33.3K | ﹤0.01% | 1050 |
|
Other funds holding CPRX
VCM
DM
VPM
Squarepoint's CPRX Position: Q1 2026 in Review
Squarepoint sold out of Catalyst Pharmaceutical (CPRX) in Q1 2026, closing a stake of 27,629 shares — an estimated $645K sold.
Squarepoint first reported a position in CPRX in Q2 2016 and held it in 26 quarters. The position peaked at $3.77M in Q4 2019. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.
- Squarepoint reported no remaining Catalyst Pharmaceutical position as of Q1 2026 after selling out during the quarter.
- Squarepoint sold 27,629 Catalyst Pharmaceutical shares in Q1 2026, an estimated $645K.
- Squarepoint first reported a position in Catalyst Pharmaceutical in Q2 2016 and held it in 26 quarters.
- Squarepoint's Catalyst Pharmaceutical position peaked at $3.77M in Q4 2019.
- 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.